Business
Voting Rights
Voting Rights.
About this update from Aura Renewable Acquisitions Plc
[{"type":"text","content":"\n Ardana PLC\n28 February 2008\n\n Ardana plc\n VOTING RIGHTS AND CAPITAL\n\n\n\nEdinburgh, UK, February 28, 2008: Ardana plc (LSE:ARA), in conformity with the\nTransparency Directive's transitional provision 6, today notifies the market of\nthe following:\n\n\nAs at 28 February 2008, the issued share capital and voting rights of Ardana plc\nare as follows:\n\n\nArdana plc's capital consists of 65,511,729 ordinary 1p shares with voting\nrights attached of one vote per ordinary share of which 12,681 ordinary shares\nare held in Treasury.\n\n\nTherefore, the total number of voting rights in Ardana plc is 65,499,048.\n\n\nThe above figure (65,499,048) may be used by shareholders as the denominator for\nthe calculations by which they will determine if they are required to notify\ntheir interest in, or a change to their interest in, Ardana plc under the FSA's\nDisclosure and Transparency Rules.\n\n\n\n\nFor more information contact:\n\nArdana plc Financial Dynamics\nDr. Huw Jones. Chief Executive Officer Julia Phillips\nTel: + 44 (0) 131 226 8550 Emma Thompson\n Tel: +44 (0)20 7831 3113\n\n\n\nArdana plc (LSE: ARA) is an emerging pharmaceutical company focused on the\ndiscovery, development and marketing of innovative products to improve human\nreproductive health, a $25.5 billion market.\n\nArdana's lead products are summarised below:\n\n\n\n • Teverelix LA, in development for three initial indications (prostate\n cancer, benign prostatic hyperplasia and endometriosis);\n • ARD-0705 a growth hormone secretagogue in Phase III for the diagnosis of\n growth hormone deficiency in adults;\n • Testosterone Cream, a transdermal testosterone delivery system in\n development for the treatment of male hypogonadism, in Phase III trials;\n • Emselex(R), a once a day treatment for the symptoms of overactive bladder\n syndrome, which Ardana has exclusive UK marketing and promotion rights and\n is being distributed in collaboration with Novartis UK Limited;\n • StriantTM SR, a testosterone replacement therapy that has been launched by\n Ardana through its own sales force in the UK and through marketing partners\n in certain European countries, as a treatment for men with confirmed\n hypogonadism; and\n • InvicorpTM, an injectable combination drug treatment for erectile\n dysfunction, for which Ardana has marketing and manufacturing ri...